Beren Therapeutics' Adrabetadex Shows Significant Efficacy in Infantile-Onset NPC
Event summary
- Beren Therapeutics presented data at the 2026 ACMG meeting showing adrabetadex reduced disease progression by 43% in infantile-onset NPC patients over 52 weeks.
- Adrabetadex-treated patients had a 71% reduction in mortality risk and an 84% 5-year survival rate compared to 42% for external controls.
- The FDA accepted Beren's NDA for adrabetadex in February 2026 with a PDUFA target action date of August 17, 2026.
The big picture
Beren Therapeutics' positive clinical data for adrabetadex positions it as a potential first-line therapy for infantile-onset NPC, a rare and fatal neurodegenerative disorder. The company's focus on cholesterol trafficking biology and cyclodextrin-based therapeutics aligns with the growing trend of targeting underlying disease pathways in rare diseases. The upcoming FDA decision will be critical in determining the commercial viability of adrabetadex.
What we're watching
- Regulatory Approval
- Whether the FDA will approve adrabetadex by the August 17, 2026 PDUFA date.
- Market Potential
- The pace at which Beren can commercialize adrabetadex if approved, given the limited treatment options for infantile-onset NPC.
- Clinical Efficacy
- How sustained the efficacy and safety data will be in longer-term follow-up studies.
Our editorial coverage:
Related topics